Clinical trials: Hospitalized COVID-19
COVID-19
Cytokine and Eicosanoid Mediators in Coronavirus Disease 2019 (COVID-19)
This study is a prospective, single center, observational, cohort study of patients to (1) describe the kinetics and temporal relationship of changes in eicosanoid and cytokine mediators in patients with severe COVID-19 admitted…
- Trial name
- NCT04452942
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- EicOsis Human Health Inc.
Covid19
Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection
Evelo will investigate the safety and efficacy of EDP1815 in the treatment of patients hospitalized with SARS-CoV-2 Infection
- Trial name
- NCT04488575
- Testing
- EDP1815
- Where
- 4 sites in United States, Turkey (Türkiye)
- Volunteers
- 16 people
- Sponsor
- Evelo Biosciences, Inc.
COVID, Vitamin D Deficiency
The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations
Although the novel SARS-CoV-2 virus (COVD-19) is classified as an acute respiratory infection, emerging data show that morbidity and mortality are driven by disseminated intravascular coagulopathy.
- Conditions
- COVID, Vitamin D Deficiency, Coagulopathy, Disseminated Intravascular Coagulation
- Trial name
- LEAD COVID-19 (NCT04363840)
- Testing
- Aspirin 81 mg, Vitamin D
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
COVID-19
Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19
This is a multicenter double blinded study to evaluate the efficacy and safety of convalescent plasma from COVID-19 recovered individuals to treat hospitalized patients with severe COVID-19 disease.
- Trial name
- EPCOvid-1 (NCT04388410)
- Testing
- convalescent plasma
- Where
- Mexico
- Volunteers
- 410 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Covid19
An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization
The purpose of this Clinical trial is to explore the therapeutic benefits of Ivermectin and Doxycycline in different combinations in high risk patients diagnosed with COVID-19.
- Trial name
- NCT04729140
- Testing
- Ivermectin Tablets, Doxycycline Tablets
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Max Health, Subsero Health
SARS-CoV 2
Muscle Mass and Strength as Predictors of Time to Discharge in Patients With COVID-19
The severe acute respiratory syndrome induced by the new coronavirus (SARS-CoV-2) has been declared a worldwide pandemic. Identifying common characteristics of the disease is crucial to promote a better prognosis for patients and…
- Trial name
- NCT04406233
- Where
- Brazil
- Volunteers
- 176 people
- Sponsor
- University of Sao Paulo
COVID-19, Lymphocytopenia
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort
Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/ kg twice a week for two weeks on immune reconstitution of lymphopenic COVID-19 patients.
- Trial name
- ILIAD-7-FR (NCT04407689)
- Testing
- Interleukin-7
- Where
- 6 sites in France
- Volunteers
- 34 people
- Sponsor
- Revimmune
COVID-19 Respiratory Infection
HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients
The primary purpose of this study is to evaluate the efficacy of HC-1119 as an adjuvant treatment for hospitalized COVID-19 male and female patients.
- Trial name
- NCT04986176
- Testing
- HC-1119
- Volunteers
- 602 people
- Sponsor
- Applied Biology, Inc.
COVID-19
Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19
This is a multi-center, randomized, triple-blind, placebo-controlled (RCT) study to evaluate the efficacy and safety of Dapsone in older adults, and/or in adult patients (≥40yrs of age) with at least one high-risk comorbidity…
- Trial name
- DAP-CORONA (NCT04935476)
- Testing
- Dapsone 85 mg PO BID
- Where
- 7 sites in United States, Canada
- Volunteers
- 3,000 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
COVID-19
Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)
Passive immunization with immunoglobulins is occasionally used as therapy for the treatment of viral infectious diseases. Immunoglobulins are used for the treatment of CMV disease, and is effective as prophylaxis when given soon…
- Trial name
- ConCoVid-19 (NCT04342182)
- Testing
- Convalescent plasma
- Where
- 18 sites in Netherlands
- Volunteers
- 86 people
- Sponsor
- Erasmus Medical Center
Respiratory Distress Syndrome
The ECOVITA Study - Validation of LUS Score in SARS-CoV-2 Disease, i.e COVID-19
Lung Ultrasound (LUS) has been revealing an extremely useful tool to identify and monitor complications from Sars-COV-2 disease.
- Trial name
- ECOVITA (NCT04871685)
- Testing
- lung ultrasound
- Where
- Italy
- Volunteers
- 950 people
- Sponsor
- University of Campania Luigi Vanvitelli
COVID-19, Coronavirus
Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults
The purpose of this study is to test the safety and efficacy of convalescent donor plasma to treat COVID-19 in hospitalized adults in a randomized, placebo-controlled setting.
- Conditions
- COVID-19, Coronavirus, SARS-CoV-2
- Trial name
- PassItOn (NCT04362176)
- Testing
- pathogen reduced SARS-CoV-2 convalescent plasma
- Where
- 26 sites in United States
- Volunteers
- 974 people
- Sponsor
- Vanderbilt University Medical Center
COVID -19
C Reactive Protein in Home Quarantined Coronavirus Disease 2019 (COVID -19) Patients.
During the peak of the second COVID -19 wave, the hospitals were over-crowded. Many COVID -19 positive patients had to stay at home and reach out to their family physicians for guidance.
- Trial name
- NCT04935515
- Testing
- Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins, Oral low dose steroid, Intravenous Antibiotics with Low dose steroid.
- Where
- India
- Volunteers
- 25 people
- Sponsor
- Manimarane Arjunan, MD,DM (Cardiology)
SARS-CoV-2 Positive Patients
Follow-up Study of COVID-19 Patients in the District Konstanz
This is a prospective single-center study for the follow-up of SARS-CoV-2 positive patients in the district of Konstanz (LKN). As part of the coronavirus pandemic, patients with SARS-CoV-2 infection are currently being treated in…
- Trial name
- FSC19-KN (NCT04724434)
- Where
- Germany
- Volunteers
- 526 people, healthy volunteers welcome
- Sponsor
- Hegau-Bodensee-Klinikum Singen
COVID-19
Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients
This is a randomized, double-blind, placebo-controlled, superiority phase IIa trial to assess the safety and efficacy of dupilumab use in hospitalized patients with moderate to severe COVID-19 infection.
- Trial name
- SafeDrop (NCT04920916)
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Virginia
Coronavirus Disease (COVID-19)
Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)
This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as assessed by the rate of sustained recovery…
- Trial name
- NCT04575584
- Testing
- Molnupiravir
- Where
- 89 sites in United States, Brazil and 15 more
- Volunteers
- 304 people
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19
Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the Treatment of Hospitalized COVID-19 Patients and Continued Treatment Following Discharge
The study is a prospective, pilot study aimed to test the safety of Tumor Treating Fields (TTFields) concomitant with best standard of care, for the treatment of hospitalized COVID-19 patients and continued treatment after…
- Trial name
- NCT04953234
- Testing
- NovoTTF-100L
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- NovoCure GmbH
COVID-19
Physical Activity and the Course of COVID-19
Being active has a beneficial effect on human immunology. Patients hospitalized for COVID-19 (coronavirus disease 2019) will be surveyed for their prior physical activity.
- Trial name
- NCT05200767
- Testing
- completing surveys
- Where
- 2 sites in Poland
- Volunteers
- 140 people
- Sponsor
- Wroclaw Medical University
SARS-CoV-2 Infection, COVID-19
The Vietnam Chloroquine Treatment on COVID-19
COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. There is currently no vaccine to prevent COVID-19 or therapeutic agent to treat COVID-19.
- Trial name
- VICO (NCT04328493)
- Testing
- Chloroquine phosphate
- Where
- 5 sites in Vietnam
- Volunteers
- 10 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
COVID-19, SARS-CoV-2
LatInamerican Vaccine Effectiveness Against Hospitalizations Due to Circulating COVID-19 VoC RWE Study
COVID-19 is the infectious disease caused by the novel coronavirus known as SARS-CoV-2, that appeared in 2019. The World Health Organisation (WHO) declared the novel coronavirus a pandemic on 11 March 2020.
- Trial name
- LIVE (NCT05282017)
- Where
- 9 sites in Brazil, Colombia and 3 more
- Volunteers
- 792 people
- Sponsor
- AstraZeneca